纳米技术方法的发展,以提高自然物质的抗疟疾潜力
Yoana Yoncheva1, Lyubomira Radeva2, Krassimira Yoncheva2
1Faculty of Medicine, Medical University of Sofia, 1431 Sofia, Bulgaria.
Molecules (Basel, Switzerland)
|October 29, 2025
概括
纳米封装增强了天然抗疟疾化合物的生物可用性,解决了药物耐药性和毒性等挑战. 这种方法提高了疟疾治疗的有效性,疟疾是一个重大的全球健康威胁.
科学领域:
- 药理学 药理学是指药理学的学科.
- 纳米技术纳米技术
- 药用化学 医学化学
背景情况:
- 疟疾仍然是一个关键的全球卫生问题,每年有数百万病例报告.
- 目前的抗疟疾疗法面临诸多挑战,包括复杂的病变发生,耐药性和不良毒性.
- 天然化合物具有潜力,但通常具有较差的水溶性和有限的生物可用性.
研究的目的:
- 对天然抗疟疾剂的纳米封装策略进行审查.
- 突出纳米封装在克服可溶性和生物利用性限制方面的潜力.
- 探索结合天然剂和绿色合成金属纳米颗粒用于疟疾治疗的使用.
主要方法:
- 对自然抗疟疾化合物的纳米封装现有文献的审查.
- 分析涉及素,素,素和素纳米配方的研究.
- 检查多种药物的联合输送和金属纳米颗粒的绿色合成研究.
主要成果:
- 纳米封装技术 (纳米囊,脂质体,脂质纳米颗粒) 显著提高了天然抗疟药的可溶性和生物利用性.
- 已经确立的药物,如素和素,以及新兴的化合物,如皮佩林和奎尔丁,在纳米封装时显示出增强的疗效.
- 同时加载多种药物和使用绿色合成的金属纳米颗粒为新型疟疾疗法提供了有希望的途径.
结论:
- 纳米封装是一种可行的策略,可以增强天然抗疟疾分子的治疗潜力.
- 通过纳米技术克服不良溶解度和生物可用性是开发更有效的疟疾治疗的关键.
- 对组合疗法和绿色合成纳米颗粒的进一步研究可能会导致先进的抗疟疾药物开发.
相关概念视频
Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


